Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Alveolar Soft Part 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Prochlorperazine × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡